Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29


Patterns and functional implications of rare germline variants across 12 cancer types.

Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, Huang KL, Wyczalkowski MA, Jayasinghe R, Banerjee T, Ning J, Tripathi P, Zhang Q, Niu B, Ye K, Schmidt HK, Fulton RS, McMichael JF, Batra P, Kandoth C, Bharadwaj M, Koboldt DC, Miller CA, Kanchi KL, Eldred JM, Larson DE, Welch JS, You M, Ozenberger BA, Govindan R, Walter MJ, Ellis MJ, Mardis ER, Graubert TA, Dipersio JF, Ley TJ, Wilson RK, Goodfellow PJ, Raphael BJ, Chen F, Johnson KJ, Parvin JD, Ding L.

Nat Commun. 2015 Dec 22;6:10086. doi: 10.1038/ncomms10086.


Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory.

Strom CM, Rivera S, Elzinga C, Angeloni T, Rosenthal SH, Goos-Root D, Siaw M, Platt J, Braastadt C, Cheng L, Ross D, Sun W.

PLoS One. 2015 Aug 21;10(8):e0136419. doi: 10.1371/journal.pone.0136419.


Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.

Adachi M, Banno K, Yanokura M, Iida M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Ueki A, Hirasawa A, Tominaga E, Aoki D.

Mol Clin Oncol. 2015 Mar;3(2):267-273.


Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.

Jönsson JM, Bartuma K, Dominguez-Valentin M, Harbst K, Ketabi Z, Malander S, Jönsson M, Carneiro A, Måsbäck A, Jönsson G, Nilbert M.

Fam Cancer. 2014 Dec;13(4):537-45. doi: 10.1007/s10689-014-9728-1.


Translational genomics in cancer research: converting profiles into personalized cancer medicine.

Patel L, Parker B, Yang D, Zhang W.

Cancer Biol Med. 2013 Dec;10(4):214-20. doi: 10.7497/j.issn.2095-3941.2013.04.005. Review.


Ovarian cancer: can proteomics give new insights for therapy and diagnosis?

Toss A, De Matteis E, Rossi E, Casa LD, Iannone A, Federico M, Cortesi L.

Int J Mol Sci. 2013 Apr 15;14(4):8271-90. doi: 10.3390/ijms14048271. Review.


BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT.

Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007.


Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.

Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, Skates SJ, Mackay J, Menon U, Jacobs IJ.

J Clin Oncol. 2013 Jan 1;31(1):49-57. doi: 10.1200/JCO.2011.39.7638.


Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.

Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W.

Pharmacogenomics. 2012 Oct;13(13):1523-35. doi: 10.2217/pgs.12.137. Review.


Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer.

Pal T, Akbari MR, Sun P, Lee JH, Fulp J, Thompson Z, Coppola D, Nicosia S, Sellers TA, McLaughlin J, Risch HA, Rosen B, Shaw P, Schildkraut J, Narod SA.

Br J Cancer. 2012 Nov 6;107(10):1783-90. doi: 10.1038/bjc.2012.452.


Genetic testing and first presymptomatic diagnosis in Moroccan families at high risk for breast/ovarian cancer.

Laarabi FZ, Jaouad IC, Ouldim K, Aboussair N, Jalil A, Gueddari BE, Benjaafar N, Sefiani A.

Oncol Lett. 2011 Mar;2(2):389-393.


Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase.

Grossi V, Simone C.

J Oncol. 2012;2012:382159. doi: 10.1155/2012/382159.


Adequacy of family history taking in ovarian cancer patients: a population-based study.

van Altena AM, van Aarle S, Kiemeney LA, Hoogerbrugge N, Massuger LF, de Hullu JA.

Fam Cancer. 2012 Sep;11(3):343-9. doi: 10.1007/s10689-012-9518-6.


Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.

Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K, Robson ME.

BJU Int. 2012 Mar;109(5):713-9. doi: 10.1111/j.1464-410X.2011.10292.x.


Recent progress in the diagnosis and treatment of ovarian cancer.

Jelovac D, Armstrong DK.

CA Cancer J Clin. 2011 May-Jun;61(3):183-203. doi: 10.3322/caac.20113.


Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.

Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):745-50. doi: 10.1073/pnas.1016538108.


The inherited genetics of ovarian and endometrial cancer.

Gayther SA, Pharoah PD.

Curr Opin Genet Dev. 2010 Jun;20(3):231-8. doi: 10.1016/j.gde.2010.03.001. Review.


The biology of ovarian cancer: new opportunities for translation.

Bast RC Jr, Hennessy B, Mills GB.

Nat Rev Cancer. 2009 Jun;9(6):415-28. doi: 10.1038/nrc2644. Review.

Items per page

Supplemental Content

Support Center